Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003552 · ClinicalTrials.gov registry record · Phase 1
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
A Phase 1 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00003552: Clinical Trial Phase 1 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00003552 is a Phase 1 study that was terminated before completion, run by National Heart, Lung, and Blood Institute (NHLBI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003552, a Phase 1 study, was terminated before completion, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy plus peripheral stem cell transplantation in treating patients with metastatic melanoma.
Interventions
- DRUG fludarabine
- DRUG cyclophosphamide
- DRUG anti-thymocyte globulin
- DRUG allogeneic lymphocytes
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-01 |
| Est. Completion | 2002-10 |
| Phase | Phase 1 |
Why NCT00003552 stopped before completion
NCT00003552 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which fludarabine is the first listed.
NCT00003552 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003552 about?
NCT00003552 is a clinical study titled "Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of chem...
What is the current status of trial NCT00003552?
This trial is currently terminated. It is a Phase 1 study. The study started on 1999-01. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00003552?
The interventions under investigation include: fludarabine (DRUG), cyclophosphamide (DRUG), anti-thymocyte globulin (DRUG), allogeneic lymphocytes (DRUG).
Who is sponsoring clinical trial NCT00003552?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia